UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2020-07, Vol.52 (1), p.73-84

2020

Volltextzugriff (PDF)

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Inflammatory bowel diseases, 2012-01, Vol.18 (1), p.1-9

2012

Volltextzugriff (PDF)

Stopping Biologics in IBD-What Is the Evidence?

Inflammatory bowel diseases, 2018-03, Vol.24 (4), p.725-731

Louis, Edouard

2018

Volltextzugriff (PDF)

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

The American journal of gastroenterology, 2012-12, Vol.107 (12), p.1770-1776

2012

Volltextzugriff (PDF)

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

The American journal of gastroenterology, 2002-09, Vol.97 (9), p.2357-2363

2002

Volltextzugriff (PDF)

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Inflammatory bowel diseases, 2019-01, Vol.25 (1), p.156-162

2019

Volltextzugriff (PDF)

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

Inflammatory bowel diseases, 2014-06, Vol.20 (6), p.978-986

2014

Volltextzugriff (PDF)

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Inflammatory bowel diseases, 2024-02, Vol.30 (2), p.240-246

2024

Volltextzugriff (PDF)

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

Alimentary pharmacology & therapeutics, 2017-01, Vol.45 (2), p.205-221

2017

Volltextzugriff (PDF)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2017-03, Vol.23 (3), p.333-340

2017

Volltextzugriff (PDF)

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Alimentary pharmacology & therapeutics, 2021-09, Vol.54 (6), p.779-791

2021

Volltextzugriff (PDF)

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Inflammatory bowel diseases, 2013-05, Vol.19 (6), p.1112-1122

2013

Volltextzugriff (PDF)

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Alimentary pharmacology & therapeutics, 2019-12, Vol.50 (11-12), p.1204-1213

2019

Volltextzugriff (PDF)

Development of the Crohn's disease digestive damage score, the Lémann score

Inflammatory bowel diseases, 2011-06, Vol.17 (6), p.1415-1422

2011

Volltextzugriff (PDF)

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Alimentary pharmacology & therapeutics, 2012-12, Vol.36 (11-12), p.1040-1048

2012

Volltextzugriff (PDF)

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

Alimentary Pharmacology & Therapeutics (Suppl), 2023-03, Vol.57 (5), p.496-508

2023

Volltextzugriff (PDF)

Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID

Inflammatory bowel diseases, 2022-08, Vol.28 (8), p.1198-1206

2022

Volltextzugriff (PDF)

Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases

Inflammatory bowel diseases, 2022-02, Vol.28 (2), p.208-217

2022

Volltextzugriff (PDF)

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Inflammatory bowel diseases, 2018-04, Vol.24 (5), p.1099-1105

2018

Volltextzugriff (PDF)

Determinants of IBD‐related disability: a cross‐sectional survey from the GETAID

Alimentary Pharmacology & Therapeutics (Suppl), 2021-05, Vol.53 (10), p.1098-1107

2021

Volltextzugriff (PDF)

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Inflammatory bowel diseases, 2013-09, Vol.19 (10), p.2111-2117

2013

Volltextzugriff (PDF)

Thiopurine metabolites and TPMT activity measurement in inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2011-11, Vol.34 (9), p.1138-1139

Louis, E.

2011

Volltextzugriff (PDF)

Evolving definitions of remission in Crohn's disease

Inflammatory bowel diseases, 2013-07, Vol.19 (8), p.1645-1653

2013

Volltextzugriff (PDF)

Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings

Neurogastroenterology and motility, 2009-04, Vol.21 (4), p.378-388

2009

Volltextzugriff (PDF)

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

United European gastroenterology journal, 2021-05, Vol.9 (4), p.451-460

2021

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library Journals Frontfile Complete

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(70)

Publikationsform

Artikel
(77)

Sprache

Englisch
(77)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review article: withdrawal of 5‐aminosalicylates in inflammatory bowel disease

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE

Stopping Biologics in IBD-What Is the Evidence?

Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process

Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease

Early Mucosal Healing Predicts Favorable Outcomes in Patients With Moderate to Severe Ulcerative Colitis Treated With Golimumab: Data From the Real-life BE-SMART Cohort

Alterations in the intestinal microbiome (dysbiosis) as a predictor of relapse after infliximab withdrawal in Crohn's disease

In-Depth Assessment of Endoscopic Remission in Inflammatory Bowel Disease Treated by Anti-TNF or Vedolizumab

Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases

Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

Expert consensus: practical algorithms for management of inflammatory bowel disease patients presenting with back pain or peripheral arthropathies

Development of the Crohn's disease digestive damage score, the Lémann score

Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

Effect of risankizumab on health‐related quality of life in patients with Crohn's disease: results from phase 3 MOTIVATE, ADVANCE and FORTIFY clinical trials

Bariatric Surgery in Patients With Inflammatory Bowel Disease: A Case-Control Study from the GETAID

Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases

Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study

Determinants of IBD‐related disability: a cross‐sectional survey from the GETAID

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy

Thiopurine metabolites and TPMT activity measurement in inflammatory bowel disease

Evolving definitions of remission in Crohn's disease

Dyspeptic symptoms in the general population: a factor and cluster analysis of symptom groupings

International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases

Aktive Filter

Suchergebnisse filtern